Contrasting of Ardelyx Inc. (ARDX) and Incyte Corporation (NASDAQ:INCY)

Ardelyx Inc. (NASDAQ:ARDX) and Incyte Corporation (NASDAQ:INCY) compete with each other in the Biotechnology sector. We will analyze and compare their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ardelyx Inc. 44.52M 3.63 53.32M -0.96 0.00
Incyte Corporation 1.80B 9.60 109.20M -0.52 0.00

Table 1 demonstrates Ardelyx Inc. and Incyte Corporation’s gross revenue, earnings per share and valuation.

Profitability

Table 2 has Ardelyx Inc. and Incyte Corporation’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Ardelyx Inc. -119.77% -37.2% -29%
Incyte Corporation -6.07% -6.4% -4.6%

Risk & Volatility

Ardelyx Inc.’s volatility measures that it’s 38.00% more volatile than S&P 500 due to its 1.38 beta. Incyte Corporation’s 0.00% less volatile than S&P 500 volatility due to the stock’s 1 beta.

Liquidity

Ardelyx Inc.’s Current Ratio and Quick Ratio are 12.8 and 12.8 respectively. The Current Ratio and Quick Ratio of its competitor Incyte Corporation are 4 and 4 respectively. Ardelyx Inc. therefore has a better chance of paying off short and long-term obligations compared to Incyte Corporation.

Analyst Ratings

The table shown features the ratings and recommendations for Ardelyx Inc. and Incyte Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ardelyx Inc. 0 0 1 3.00
Incyte Corporation 0 3 4 2.57

Ardelyx Inc.’s consensus target price is $7, while its potential upside is 169.23%. Competitively Incyte Corporation has an average target price of $81.6, with potential upside of 0.67%. The information presented earlier suggests that Ardelyx Inc. looks more robust than Incyte Corporation as far as analyst view.

Insider & Institutional Ownership

The shares of both Ardelyx Inc. and Incyte Corporation are owned by institutional investors at 85.2% and 94% respectively. Insiders owned roughly 1.4% of Ardelyx Inc.’s shares. Insiders Comparatively, owned 0.3% of Incyte Corporation shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ardelyx Inc. -10.29% -28.86% -35.79% -39.75% -58.99% -63.03%
Incyte Corporation 1.82% -5.23% -4.36% -5.68% -31.01% -30.93%

For the past year Ardelyx Inc.’s stock price has bigger decline than Incyte Corporation.

Summary

Incyte Corporation beats Ardelyx Inc. on 8 of the 12 factors.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The companyÂ’s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the companyÂ’s clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.